These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9457493)
1. Effect of miglitol administration to non-insulin-dependent diabetic rats. Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493 [TBL] [Abstract][Full Text] [Related]
2. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose. Axen KV; Li X; Sclafani A Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734 [TBL] [Abstract][Full Text] [Related]
3. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Johnson AB; Taylor R Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851 [TBL] [Abstract][Full Text] [Related]
4. In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats. Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE Can J Physiol Pharmacol; 1996 Nov; 74(11):1196-203. PubMed ID: 9028577 [TBL] [Abstract][Full Text] [Related]
5. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Joubert PH; Venter HL; Foukaridis GN Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417 [TBL] [Abstract][Full Text] [Related]
6. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Scott LJ; Spencer CM Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834 [TBL] [Abstract][Full Text] [Related]
7. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288 [TBL] [Abstract][Full Text] [Related]
8. Miglitol, a new alpha-glucosidase inhibitor. Sels JP; Huijberts MS; Wolffenbuttel BH Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557 [TBL] [Abstract][Full Text] [Related]
9. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Russell JC; Graham SE; Dolphin PJ Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143 [TBL] [Abstract][Full Text] [Related]
10. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806 [TBL] [Abstract][Full Text] [Related]
11. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. Heinz G; Komjati M; Korn A; Waldhäusl W Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007 [TBL] [Abstract][Full Text] [Related]
12. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693 [TBL] [Abstract][Full Text] [Related]
13. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor]. Kuboyama N; Hayashi I; Yamaguchi T Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808 [No Abstract] [Full Text] [Related]
15. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468 [TBL] [Abstract][Full Text] [Related]
16. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025 [TBL] [Abstract][Full Text] [Related]
17. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase. Joubert PH; Foukaridis GN; Bopape ML Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325 [TBL] [Abstract][Full Text] [Related]
18. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms. Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880 [TBL] [Abstract][Full Text] [Related]
19. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624 [TBL] [Abstract][Full Text] [Related]